David McIntyre
Equibles does not estimate personal net worth.
Get an email with a short summary when Inhibikase Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get IKT alertsAbout David McIntyre
David McIntyre is recorded as CFO at Inhibikase Therapeutics, Inc. (IKT). The newest filing on record that lists David McIntyre as CFO at Inhibikase Therapeutics, Inc. (IKT) is dated April 30, 2026. Inhibikase Therapeutics, Inc. reported in an 8-K filed April 14, 2025 that David McIntyre was appointed Chief Financial Officer, principal financial officer and principal accounting officer, effective April 14, 2025. The proxy statement of Inhibikase Therapeutics, Inc. reports total compensation of $5,519,690 for David McIntyre in fiscal 2025, including a base salary of $347,216. Inhibikase Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inhibikase Therapeutics, Inc. includes Mark Iwicki (CEO and Board Member), Amit Munshi (Chairman and Board Member), Roberto Bellini (Chairman and Board Member) and 4 others.
“Effective April 14, 2025, the Board appointed David McIntyre as Chief Financial Officer, principal financial officer and principal accounting officer of the Company (the “Appointment”).”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 30, 2026
Company network
Leadership on record at Inhibikase Therapeutics, Inc.
- Mark Iwicki CEO, Board Member
- Amit Munshi Chairman, Board Member
- Roberto Bellini Chairman, Board Member
- Arvind Kush Board Member
- David Canner Board Member
- Scott Wasserman Board Member
- Vincent Aurentz Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Inhibikase Therapeutics, Inc. (IKT) | Chief Financial Officer | $347,216 | $5,519,690 |